Voloridge Investment Management
GPCR icon

Voloridge Investment Management’s Structure Therapeutics GPCR Stock Holding History

Voloridge Investment Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.3M Buy
254,969
+4,969
+2% +$340K 0.05% 451
2025
Q4 		$17.4M Buy
+250,000
New +$10.2M 0.06% 406

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Voloridge Investment Management's GPCR Position: Q1 2026 in Review

Voloridge Investment Management increased its Structure Therapeutics (GPCR) stake by 2% in Q1 2026, buying an estimated $340K and bringing the position to 254,969 shares worth $12.3M. The position accounts for 0.05% of the portfolio, ranked #451.

Voloridge Investment Management first reported a position in GPCR in Q4 2025 and has held it in 2 quarters since. The position peaked at $17.4M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Voloridge Investment Management held 254,969 shares of Structure Therapeutics worth $12.3M as of Q1 2026.
  • Voloridge Investment Management bought 4,969 Structure Therapeutics shares in Q1 2026, an estimated $340K.
  • Structure Therapeutics made up 0.05% of Voloridge Investment Management's portfolio in Q1 2026, its #451 holding.
  • Voloridge Investment Management first reported a position in Structure Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Voloridge Investment Management's Structure Therapeutics position peaked at $17.4M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.